NCT06569758View on ClinicalTrials.gov

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

September 2, 2027

Study Completion Date

December 13, 2027

Conditions
SafetyTolerabilityGenSci098Thyroid Eye Disease (TED)
Interventions
DRUG

GenSci098

subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.

DRUG

GenSci098 Placebo

In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication, Shanghai

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY